Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
Top Cited Papers
Open Access
- 10 November 2004
- journal article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 2 (11), 1924-1933
- https://doi.org/10.1111/j.1538-7836.2004.00955.x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemiaBlood, 2003
- Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisCritical Care Medicine, 2003
- High plasma fibrinogen level is associated with poor clinical outcome in DIC patientsAmerican Journal of Hematology, 2002
- Disseminated Intravascular Coagulation in SepsisSeminars in Thrombosis and Hemostasis, 2001
- Coagulation Blockade Prevents Sepsis-induced Respiratory and Renal Failure in BaboonsAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisThe New England Journal of Medicine, 2001
- Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular CoagulationThrombosis and Haemostasis, 2001
- Disseminated Intravascular CoagulationThe New England Journal of Medicine, 1999
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1992
- Septic Shock, Multiple Organ Failure, and Disseminated Intravascular CoagulationSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1992